▲ +204.96% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Agile Therapeutics in the last 3 months. The average price target is $8.60, with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 204.96% upside from the last price of $2.82.
The current consensus among 6 investment analysts is to buy stock in Agile Therapeutics. This Buy consensus rating has held steady for over two years.
Agile Therapeutics, Inc., a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.